Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Ayşe Nur Hazar-yavuz; Gül Sinemcan Kabataş; Yusufhan Yazır; Levent Kabasakal

Article Details

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Authors:

Ayşe Nur Hazar-yavuz | Gül Sinemcan Kabataş | Yusufhan Yazır | Levent Kabasakal

Publisher:

Marmara University

Main Topics:

Medical Pharmacology

Journal:

Journal of Research in Pharmacy Vol.27 Issue 4, pp.1626-1637

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001347862

pISSN:

2630-6344

Keywords:

Abstract:

 Inflammatory bowel disease IBD is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid TNBS-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitisBB-12, colitisL. reuteri, colitisS. boulardii, colitisB. clausii and colitismethylprednisolone positive control treatment groups. Colitis was induced by the administration of intracolonically 80 mgkg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index DAI scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde MDA and glutathione GSH and activity of myeloperoxidase MPO in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

 Inflammatory bowel disease IBD is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid TNBS-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitisBB-12, colitisL. reuteri, colitisS. boulardii, colitisB. clausii and colitismethylprednisolone positive control treatment groups. Colitis was induced by the administration of intracolonically 80 mgkg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index DAI scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde MDA and glutathione GSH and activity of myeloperoxidase MPO in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

 Inflammatory bowel disease IBD is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid TNBS-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitisBB-12, colitisL. reuteri, colitisS. boulardii, colitisB. clausii and colitismethylprednisolone positive control treatment groups. Colitis was induced by the administration of intracolonically 80 mgkg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index DAI scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde MDA and glutathione GSH and activity of myeloperoxidase MPO in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

 Inflammatory bowel disease IBD is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid TNBS-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitisBB-12, colitisL. reuteri, colitisS. boulardii, colitisB. clausii and colitismethylprednisolone positive control treatment groups. Colitis was induced by the administration of intracolonically 80 mgkg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index DAI scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde MDA and glutathione GSH and activity of myeloperoxidase MPO in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

Article Details

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Authors:

Ayşe Nur Hazar-yavuz | Gül Sinemcan Kabataş | Yusufhan Yazır | Levent Kabasakal

Publisher:

Marmara University

Main Topics:

Medical Pharmacology

Journal:

Journal of Research in Pharmacy Vol.27 Issue 4, pp.1626-1637

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001347862

pISSN:

2630-6344

Probiotics

inflammatory bowel disease

experimental colitis

trinitrobenzene sulfonic acid

disease activity index

Issues

Article Details

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Authors: Ayşe Nur Hazar-yavuz | Gül Sinemcan Kabataş | Yusufhan Yazır | Levent Kabasakal

Publisher: Marmara University

Main Topics: Medical Pharmacology

Journal: Journal of Research in Pharmacy Vol.27 Issue 4, pp.1626-1637

Document Type: Article

Publication Date: 6/2025

Document Language: English

Document ID (Org No.): 2001347862

pISSN: 2630-6344

Probiotics

inflammatory bowel disease

experimental colitis

trinitrobenzene sulfonic acid

disease activity index

Issues

Authors:

Ayşe Nur Hazar-yavuz | Gül Sinemcan Kabataş | Yusufhan Yazır | Levent Kabasakal

Publisher:

Marmara University

Main Topics:

Medical Pharmacology

Journal:

Journal of Research in Pharmacy Vol.27 Issue 4, pp.1626-1637

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001347862

pISSN:

2630-6344